In the current study, we found that the expression levels of c-myc were not significantly associated with the efficacy of dinaciclib in HCC cells, but CDK9 might be the most crucial CDK among the targets of dinaciclib. The gene discussed is CDK9; the disease is hepatocellular carcinoma.